These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1450297)

  • 1. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.
    Goodnick PJ; Sandoval R; Brickman A; Klimas NG
    Biol Psychiatry; 1992 Nov; 32(9):834-8. PubMed ID: 1450297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bupropion slow-release response in depression: diagnosis and biochemistry.
    Goodnick PJ; Dominguez RA; DeVane CL; Bowden CL
    Biol Psychiatry; 1998 Oct; 44(7):629-32. PubMed ID: 9787888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study].
    Raucoules D; Levy C; Azorin JM; Bruno M; Valli M
    Encephale; 1992; 18(6):611-6. PubMed ID: 1285270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
    Ko HC; Lu RB; Shiah IS; Hwang CC
    Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.
    De Bellis MD; Geracioti TD; Altemus M; Kling MA
    Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):636-41. PubMed ID: 7687151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
    Schönfeldt-Lecuona C; Connemann BJ; Wolf RC; Braun M; Freudenmann RW
    Pharmacopsychiatry; 2006 Jul; 39(4):152-4. PubMed ID: 16871471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.
    Vercoulen JH; Swanink CM; Zitman FG; Vreden SG; Hoofs MP; Fennis JF; Galama JM; van der Meer JW; Bleijenberg G
    Lancet; 1996 Mar; 347(9005):858-61. PubMed ID: 8622391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study.
    Salzman C; Jimerson D; Vasile R; Watsky E; Gerber J
    Biol Psychiatry; 1993 Oct; 34(8):569-71. PubMed ID: 8274586
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
    Walker PW; Cole JO; Gardner EA; Hughes AR; Johnston JA; Batey SR; Lineberry CG
    J Clin Psychiatry; 1993 Dec; 54(12):459-65. PubMed ID: 8276736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of dexamethasone on plasma homovanillic acid and 3-methoxy-4-hydroxyphenylglycol. Evidence for abnormal corticosteroid-catecholamine interactions in major depression.
    Wolkowitz OM; Doran AR; Breier A; Roy A; Jimerson DC; Sutton ME; Golden RN; Paul SM; Pickar D
    Arch Gen Psychiatry; 1987 Sep; 44(9):782-9. PubMed ID: 3632251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
    Amsterdam JD; Shults J; Rutherford N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemistry and paroxetine response in major depression.
    Goodnick PJ; Henry J; Kumar A
    Biol Psychiatry; 1995 Mar; 37(6):417-9. PubMed ID: 7772652
    [No Abstract]   [Full Text] [Related]  

  • 16. Bupropion in depression. I. Biochemical effects and clinical response.
    Golden RN; Rudorfer MV; Sherer MA; Linnoila M; Potter WZ
    Arch Gen Psychiatry; 1988 Feb; 45(2):139-43. PubMed ID: 3122698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma-free and sulfoconjugated MHPG in major depressive disorders: differences between responders to treatment and nonresponders.
    Mine K; Okada M; Mishima N; Fujiwara M; Nakagawa T
    Biol Psychiatry; 1993 Nov; 34(9):654-60. PubMed ID: 8292695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.
    Little JT; Ketter TA; Mathé AA; Frye MA; Luckenbaugh D; Post RM
    Biol Psychiatry; 1999 Feb; 45(3):285-9. PubMed ID: 10023503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotropic treatment of chronic fatigue syndrome and related disorders.
    Goodnick PJ; Sandoval R
    J Clin Psychiatry; 1993 Jan; 54(1):13-20. PubMed ID: 8428892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
    Blier P; Ward HE; Tremblay P; Laberge L; Hébert C; Bergeron R
    Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.